// App-Quantinova.ai

[FRI0161] : A PHASE 1B/2A STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XMAB5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS

Researchers

Presenter

  • M. Jaraczewska-Baumann

Principal Investigators

  • M. Korkosz

  • G. Sulyok

  • P. Sramek

  • B. Rojkovich

  • S. Daniluk

  • J. Bartalos

  • D.J. Zack

  • P. Foster

Medical Centers

  • The University Hospital, Krakow, Poland

  • PRA CZ, Praha, Czech Republic

  • Budai Irgalmasrendi Hospital, Rheumatology II, Budapest, Hungary

  • NZOZ Center of Osteoporosis and Osteoarticular Diseases, Bialystok, Poland

  • Polyclinic of the Hospitaller Brothers of St John of God, Budapest, Hungary

Locations

  • Poland

  • Czech Republic

  • Hungary

Companies

  • Xencor Inc.

  • Drug Research Center

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

  • Venous thrombosis

  • Inflammatory Arthritis

Biomarkers

  • Cluster of Differentiation 19

  • Albumin/creatinine

Drug/Treatment

  • XmAb5871

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved